Cabozantinib (Cometriq) is available on the NHS as a possible treatment for progressive medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease.
Information and support
NHS Choices may be a good place to find out more.
These organisations can give you advice and support:
- Butterfly Thyroid Cancer Trust, 01207 545 469
- AMEND, 01892 516 076
- Macmillan Cancer Support, 0808 808 0000
- Cancer Research UK, 0808 800 4040.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
This page was last updated: 28 March 2018